Published in J Theor Biol on August 08, 2007
Why must T cells be cross-reactive? Nat Rev Immunol (2012) 1.88
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Concern Co-Receptor CD8-Mediated Modulation of T-Cell Receptor Functional Sensitivity and Epitope Recognition Degeneracy. Front Immunol (2013) 1.41
CD8 controls T cell cross-reactivity. J Immunol (2010) 1.15
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods (2008) 1.03
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol (2011) 0.94
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92
Insights into T cell recognition of antigen: significance of two-dimensional kinetic parameters. Front Immunol (2012) 0.87
The T cell antigen receptor: the Swiss army knife of the immune system. Clin Exp Immunol (2015) 0.82
Cellular-level versus receptor-level response threshold hierarchies in T-cell activation. Front Immunol (2013) 0.81
Proximity of TCR and its CD8 coreceptor controls sensitivity of T cells. Immunol Lett (2013) 0.78
To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.78
CD8(+) T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunol Cell Biol (2016) 0.75
Targeted suppression of autoreactive CD8(+) T-cell activation using blocking anti-CD8 antibodies. Sci Rep (2016) 0.75
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
RcsCDB His-Asp phosphorelay system negatively regulates the flhDC operon in Escherichia coli. Mol Microbiol (2003) 2.33
Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem (2007) 1.95
Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol (2005) 1.94
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem (2003) 1.92
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 1.92
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods (2008) 1.62
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity (2009) 1.55
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem (2009) 1.51
Structural basis for ineffective T-cell responses to MHC anchor residue-improved "heteroclitic" peptides. Eur J Immunol (2014) 1.49
Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol (2010) 1.48
Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol (2012) 1.46
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res (2005) 1.43
Concern Co-Receptor CD8-Mediated Modulation of T-Cell Receptor Functional Sensitivity and Epitope Recognition Degeneracy. Front Immunol (2013) 1.41
Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology (2008) 1.40
Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood (2011) 1.39
Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res (2013) 1.36
Structural and biophysical determinants of αβ T-cell antigen recognition. Immunology (2012) 1.30
Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem (2004) 1.29
High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol (2003) 1.28
Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A (2008) 1.26
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol (2007) 1.24
CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. J Immunol (2005) 1.21
Genetic and structural basis for selection of a ubiquitous T cell receptor deployed in Epstein-Barr virus infection. PLoS Pathog (2010) 1.18
T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol (2008) 1.18
Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res (2008) 1.15
CD8 controls T cell cross-reactivity. J Immunol (2010) 1.15
A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev (2012) 1.14
Peptide length determines the outcome of TCR/peptide-MHCI engagement. Blood (2012) 1.13
Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest (2008) 1.09
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods (2008) 1.03
Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol (2007) 1.01
The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther (2007) 1.01
Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol (2005) 1.01
Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol (2002) 0.99
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem (2012) 0.96
CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol (2007) 0.96
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. J Immunol (2011) 0.94
The molecular determinants of CD8 co-receptor function. Immunology (2012) 0.94
T-cell receptor specificity maintained by altered thermodynamics. J Biol Chem (2013) 0.94
T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem (2013) 0.93
Peptide-major histocompatibility complex dimensions control proximal kinase-phosphatase balance during T cell activation. J Biol Chem (2009) 0.93
Dyslipidemia due to retroviral protease inhibitors. Nat Med (2002) 0.93
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92
A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape. Retrovirology (2015) 0.90
Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity. J Clin Invest (2016) 0.90
Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers. Sci Rep (2012) 0.90
Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol (2010) 0.90
TCR/pMHC Optimized Protein crystallization Screen. J Immunol Methods (2012) 0.89
Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope. J Virol (2012) 0.89
Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes (2012) 0.89
Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur J Immunol (2010) 0.88
Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity. Immunology (2013) 0.87
Agr interference between clinical Staphylococcus aureus strains in an insect model of virulence. J Bacteriol (2006) 0.87
Novel CD8+ T cell antagonists based on beta 2-microglobulin. J Biol Chem (2002) 0.87
Functional and biophysical characterization of an HLA-A*6801-restricted HIV-specific T cell receptor. Eur J Immunol (2007) 0.87
Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. Eur J Immunol (2006) 0.87
Specific T-cell activation in an unspecific T-cell repertoire. Sci Prog (2011) 0.86
Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection. Nat Commun (2012) 0.86
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol (2013) 0.86
Use of peptide-major histocompatibility complex tetramer technology to study interactions between Staphylococcus aureus proteins and human cells. Infect Immun (2007) 0.85
The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2. Cancer Immunol Immunother (2006) 0.82